Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496769 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,421
- Enrollment target
NCT00496769 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 6,421 participants.
The verdict
NCT00496769, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,421 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
Interventions
- DRUG Apixaban
- DRUG Acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,421 participants |
| Start Date | 2007-08-31 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496769
The ClinicalTrials.gov registry entry for NCT00496769 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT00496769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496769 about?
NCT00496769 is a clinical study titled "A Phase III Study of Apixaban in Patients With Atrial Fibrillation". The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
What is the current status of trial NCT00496769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,421 participants. The study started on 2007-08-31. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT00496769?
The interventions under investigation include: Apixaban (DRUG), Acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT00496769?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.